GLP-1受体激动剂在2型糖尿病合并冠心病治疗中的作用研究进展  

Research Progress in Role of GLP-1 Receptor Agonist in Treatment of Type 2 Diabetes with Coronary Heart Disease

作　　者：刘可欣 孙东倩 刘传亮[2] LIU Kexin;SUN Dongqian;LIU Chuanliang(School of Clinical Medicine,Weifang Medical University,Weifang 261053,China;Department One of Geriatrics,Weifang People′s Hospital,Weifang 261000,China)

机构地区：[1]潍坊医学院临床医学院,山东潍坊261053 [2]潍坊市人民医院老年医学一科,山东潍坊261000

出　　处：《医学综述》2023年第19期3909-3914,共6页Medical Recapitulate

基　　金：山东省科技发展计划项目(LKJGG2021Y046)。

摘　　要：近年来,我国2型糖尿病合并冠心病患者数量不断上升,单纯降糖药物已不能满足临床需求。随着对2型糖尿病合并冠心病致病机制认识的不断加深,发现治疗糖尿病的新型药物在稳定血糖的基础上还可延缓糖尿病相关并发症的发生发展。胰高血糖素样肽-1(GLP-1)受体激动剂作为一种新型的降糖药物不仅在控制血糖方面取得了肯定疗效,而且具有明显的心血管保护作用。目前认为,GLP-1受体激动剂保护心血管的机制主要有抗炎、抗氧化应激、抗胰岛素抵抗和抗血小板,未来对其机制深入研究可为2型糖尿病合并冠心病患者提供新的治疗选择。In recent years,the number of patients with type 2 diabetes combined with coronary heart disease has been rising in China,and simple hypoglycemic drugs can no longer meet the clinical needs.With the deepening understanding of the pathogenesis of type 2 diabetes combined with coronary heart disease,it′s discovered that new hypoglycemic drugs can also delay the occurrence and development of diabetes related complications on the basis of stabilizing blood sugar.Glucagon-like peptide-1(GLP-1)receptor agonist,as a new type of hypoglycemic drug,not only has achieved positive effects on blood glucose control,but also has obvious cardiovascular protective effect.At present,it is believed that the mechanisms of GLP-1 receptor agonist protecting cardiovascular system mainly include anti-inflammatory,antioxidant stress,anti-insulin resistance and antiplatelet.In the future,in-depth study of its mechanisms can provide new treatment options for the patients with type 2 diabetes combined with coronary heart disease.

关 键 词：糖尿病 2型 冠心病 胰高血糖素样肽-1受体激动剂 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学]